Summary
Synopsis: Diclofenac sodium1, a phenylacetic acid derivative, is a non-steroidal, anti-inflammatory, analgesic agent advocated for use in rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and allied conditions, and in the treatment of pain resulting from minor surgery, trauma and dysmenorrhoea.
Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis. Available data suggest that in patients with osteoarthritis diclofenac sodium is comparable in efficacy and tolerability with naproxen, ibuprofen, sulindac and diflunisal. As oral diclofenac is generally given in 3 divided daily doses it may be at a disadvantage relative to less frequent administration with naproxen, diflunisal and sulindac in rheumatoid arthritis, although there is some evidence of diclofenac’s efficacy when administered twice daily, or once daily as a slow release tablet. The drug is also available as suppositories and ampoules for intramuscular injection. No one of the non-steroidal anti-inflammatory agents is the most suitable drug for all patients requiring such therapy, and diclofenac should be considered along with other drugs of its type in the arthritic patient.
Pharmacology: Diclofenac sodium has been shown to be active in suppressing inflammation in non-specific animal models including carageenan-induced rat paw oedema, oedema induced by kaolin, mustard or croton oil and in suppressing granuloma formation in rats and ultraviolet-induced erythema in guinea-pigs. In these tests diclofenac has demonstrated activity at least comparable (weight for weight) with that of indomethacin and greater than that of aspirin, phenylbutazone, naproxen and flufenamic acid.
Diclofenac sodium has been demonstrated to have antipyretic activity and to be an effective analgesic in rats and mice and in therapeutic trials in patients with rheumatoid arthritis, osteoarthritis or pain of varying origin.
Controlled studies in healthy volunteers, employing 51Cr-labelled erythrocytes or endoscopy, have found commercially available oral preparations of diclofenac sodium to cause milder gastric mucosal changes than naproxen and less gastrointestinal blood loss than aspirin, naproxen or feprazone. However, the relevance of these findings after brief periods of administration to healthy subjects, to prolonged use in the treatment of arthritis diseases is not known.
In vitro, diclofenac sodium is a potent inhibitor of the secondary phase of platelet aggregation by adenosine disphosphate, but at usual therapeutic dosages oral diclofenac has little effect on platelet aggregation, or activated prothrombin time.
Diclofenac sodium is a potent, competitive and irreversible inhibitor of prostaglandin synthetase in vitro and in vivo and it is considered that much of its anti-inflammatory activity is attributable to this property.
Pharmacokinetics: Studies with single doses of oral and intravenous diclofenac sodium indicate that the orally administered drug is completely absorbed whether given as a solution or as an enteric-coated tablet. Single 50mg doses of enteric-coated tablets result in maximum plasma concentrations of about 1500ng/ml at 1.5 to 2 hours after ingestion. Plasma concentrations are significantly decreased by the concomitant administration of therapeutic doses of aspirin. Diclofenac sodium is eliminated principally by metabolism and subsequent urinary and biliary excretion of glucuronide and sulphate conjugates of the metabolites. The principal metabolite in man is the 4’-hydroxy derivative of diclofenac sodium. The amount excreted in urine accounts for 20 to 30 % of the dose and that in bile for 10 to 20%. The mean terminal elimination half life is 1.2 to 1.8 hours. In animals this metabolite possesses about 1/30th the anti-inflammatory activity of the parent drug.
Studies with single intravenous doses of 14C-labelled diclofenac in 4 patients with varying degrees of renal impairment indicate that the area under the plasma level-time curve (AUC) is markedly increased only when the creatinine clearance is 3ml/min or less, but the AUC for unchanged diclofenac sodium is not influenced by renal function. In severe renal impairment, steady-state concentrations of total metabolites for 2 daily doses of 50mg can be expected to be 4 times higher than in subjects with normal renal function.
Therapeutic Trials: In patients with active rheumatoid arthritis or osteoarthritis, diclofenac sodium has been compared with placebo, ordinary aspirin, indomethacin, ibuprofen, naproxen, phenylbutazone, sulindac, diflunisal and clofezone.
Diclofenac 75 to 150mg has been demonstrated to be superior to placebo in patients with active rheumatoid arthritis with respect to pain relief, decreased duration of morning stiffness, increase in grip strength, decrease in joint tenderness and decrease in the circumference of the proximal interphalangeal and other involved joints.
Therapeutic trials comparing diclofenac 75 to 150mg with ordinary aspirin 4 to 5g daily have been of the within-patient type, generally of short duration and have had no drug-free period between the active drug periods. No significant differences between the therapeutic efficacy of diclofenac and aspirin 4 to 5g daily was demonstrable, but diclofenac tended to be more efficacious than lower doses of aspirin. In all studies there was a tendency, which in some instances was significant, for aspirin to cause more adverse effects than diclofenac.
As in most short term studies which have compared indomethacin with other non-steroidal anti-inflammatory drugs in rheumatoid arthritis, no statistically significant difference could be demonstrated between diclofenac 75 to 150mg daily and an equal dose of indomethacin with respect to the usual assessment criteria. However, in several studies indomethacin has caused more frequent adverse effects than diclofenac. In 6-month studies there was a clear tendency for diclofenac to be superior with respect to most assessment criteria as the study progressed.
No statistically significant differences between the efficacy of diclofenac and naproxen, ibuprofen or phenylbutazone was found in limited studies. The frequency of side effects has been similar with diclofenac and each of the other drugs studied.
In patients with osteoarthritis, short term studies comparing diclofenac 75 to 150mg and indomethacin 75 to 150mg have not found significant differences between the drugs, but some studies conducted over a period of 12 to 24 weeks found diclofenac to be superior to indomethacin with respect to analgesic activity or overall improvement.
Diclofenac 75 to 150mg daily has been found to be at least as effective as relatively low doses of ibuprofen (600 to 1800mg daily) whilst no trends indicating a better effect with either drug were evident in a comparison of diclofenac 75 to 150mg and sulindac 200 to 400mg daily. Comparisons between diclofenac and naproxen have produced varying results. Design faults such as small patient numbers or lack of comparability of groups between centres in these studies necessitate further well designed trials to determine the relative merits of diclofenac and naproxen when both drugs are administered twice daily.
Long term open studies in large numbers of patients in general practice indicate an excellent or good response in about 70 to 85% of patients with rheumatoid arthritis or osteoarthritis respectively.
Open non-comparative studies in patients with ankylosing spondylitis suggest that marked or moderate symptomatic improvement occurs in 55 to 66% of patients treated for 2 to 4 weeks.
Diclofenac sodium administered either orally or intramuscularly has been studied in the relief of pain and various other symptoms in patients who have undergone minor oral surgery, tonsillectomy or anorectal surgery. Diclofenac has also been studied in post partum pain and that associated with sports injuries or other accidental trauma. Because of poor design, studies in postoperative pain provide little valid data, but suggest that diclofenac provides adequate analgesia in about three-quarters of patients. Onset of analgesia occurs 30 to 45 minutes after ingestion in most patients. In the alleviation of pain and swelling following tooth extraction, diclofenac 75mg daily was at least as effective as indomethacin 75mg and oxyphen-butazone 600mg daily. Diclofenac 150mg daily was superior to oxyphenbutazone 600mg daily in reducing swelling associated with sports injuries.
Side Effects: As with other non-steroidal anti-inflammatory drugs introduced in recent years, diclofenac has been better tolerated than moderate doses of aspirin. Gastrointestinal side effects are the most frequently reported adverse effects of diclofenac and occur in about 10% of patients. The frequency of side effects appears not to be closely related with either dosage or age. The incidence of side effects with diclofenac 75 to 125mg daily has generally been lower than with aspirin 3 to 5g daily or indomethacin 75 to 125mg daily and similar to that with naproxen, sulindac, ibuprofen or diflunisal. As with other recently introduced nonsteroidal anti-inflammatory drugs, there have been a few reports of gastrointestinal bleeding possibly associated with diclofenac.
Dosage: In adults the initial dosage is 25 to 50mg 3 times daily. The maintenance dosage should be adjusted to the minimum required for adequate control of symptoms. The tablets should be swallowed whole with or after a meal.
Similar content being viewed by others
References
Abrams, G.J.; Solomon, L. and Meyers, O.L.: A long-term study of diclophenac sodium in the treatment of rheumatoid arthritis and osteo-arthrosis. South African Medical Journal 53: 442 (1978).
Appelboom, T.; Balthazar-Letawe, D.; Boes, P.; Claessens, J. and Famaey, J.-P.: A test of 100mg Voltaren suppositories in osteoarthritis. Bruxelles-Medicale 56(6): 273–277 (1976).
Avendano-Espinosa, O.: Analgesia with diclofenac sodium in anorectal surgery. Prensa Medica Mexicana 42(7/8): 347–350 (1977).
Ayrolles, D. and Fournie, A.: Study on a new anti-inflammatory non-hormonal drug, diclofenac sodium in 50 cases. Rhumatologie 28(9) 53–56 (1976).
Bach, G.L.: Klinische Prufung von diclofenac na (Voltaren) bei Arthrosen. Therapiewoche 26(18): 2958–2965 (1976).
Bach, G.L.: The acute gouty attack: Comparative treatment with two non-steroidal antirheumatic drugs. Medizinische Welt 30: 1696 (1979).
Badia-Flores, J.; Garcia-Rubio, R. and Barradas, F.M.: Efecto sintomatico y tolerabilidad del diclofenac sodico en la artritis reumatoide. Investigacion Medica Internacional 2(3): 194–199 (1975).
Bahous, I.: Diflunisal — ein neues, lang wirksames steroidfreies Antirheumatikum. Klinische Prufung gegen Diclofenac. Schweizerische Rundschau fur Medizin (PRAXIS) 68(12): 390–393 (1979).
Barnes, C.G.; Berry, H.; Carter, M.E.; Downie, W.W.; Fowler, P.D.; Moll, J.M.H.; Perry, J.D.; Sawaf, M.S. and Wright, V.: Diclofenac sodium (Voltarol) and indomethacin: A multicentre comparative study in rheumatoid arthritis and osteoarthritis. Rheumatology Rehabilitation (Suppl. 2): 135–143 (1979).
Bethlen, L. and Dannhorn, R.: Results of testing diclofenac sodium in general practice. Therapiewoche 26: 3039–3047 (1976).
Bijlsma, A.: The long term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. Scandinavian Journal of Rheumatology (Suppl. 22): 74–80 (1978).
Bijlsma, A. and ten Pas, J.G.: A study of the anti-inflammatory effect of Voltaren in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology (Suppl. 22): 46–50 (1978).
Brackertz, D.: Comparison of clofezone and diclofenac in the treatment of out-patients suffering from activated (painful) osteoarthrosis. Zeitschrift fur Rheumatologie 37: 242–249 (1978).
Brooks, P.M.; Hill, W. and Geddes, R.: Diclofenac and ibuprofen in rheumatoid arthritis and osteoarthritis. Medical Journal of Australia 1: 29–30 (1980).
Car, A.; Jajic, I.; Krampae, I.; Vitaus, M.; Zenic, N. and Zivkovic, M.: A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip. Scandinavian Journal of Rheumatology (Suppl. 22): 63–68 (1978).
Cardoe, N. and Fowler, P.D.: Diclofenac sodium (Voltarol): A double-blind comparative study with ibuprofen in patients with rheumatoid arthritis. Rheumatology and Rehabilitation (Suppl. 2): 89–97 (1979).
Ciccolunghi, S.N.; Chaudri, H.A. and Schubiger, B.I.: How long should long be? Long-term trials in rheumatic diseases. Annals of the Rheumatic Diseases 38: 155–160 (1979c).
Ciccolunghi, S.N.; Chaudri, H.A. and Schubiger, B.I.: The value and results of long term studies with diclofenac sodium. Rheumatology and Rehabilitation (Suppl. 2): 100–110 (1979a).
Ciccolunghi, S.N.; Chaudri, H.A.; Schubiger, B.I. and Reddrop, R.: Report on a long term tolerability study of up to 2 years with diclofenac sodium (Voltaren). Scandinavian Journal of Rheumatology (Suppl. 22): 86–96 (1978).
Ciccolunghi, S.N.; Schubiger, B.I. and Reddrop, R.: Comparisons of tolerability findings in international clinical trials. Rheumatology and Rehabilitation (Suppl. 2): 122–130 (1979b).
Ciucci, A.G.: A review of spontaneously reported adverse drug reactions with diclofenac sodium. Rheumatology and Rehabilitation (Suppl. 2): 116–120 (1979).
Coimbra, F. de A.: Report from the general out-patient hospital rheumatological department, Rio de Janeiro. Voltaren. Experiencia Nac. com o Diclofenac Sodico. XI Congress of Rheumatology, Mesa-Redonda, Brasil 26 to 30 July 1976, p.27–33 (Geigy, 1977).
Coimbra, F. de A. and Seda, H.: Double-blind comparative trial with diclofenac sodium and indomethacin, combining 25mg tablets and 100mg suppositories in the treatment of rheumatoid arthritis. Revista Brasileira de Medecina 36: 166 (1979).
D’Angelo, D. and Gomes, J.V.: Experience with diclofenac sodium in Traumato-Orthopedics. Revista Brasileira de Clinica e Terapeutica 7: 766–770 (1978).
Dewijze, M.: Voltaren in traumatology. Bruxelles-Medicale 57(9): 381–386 (1977).
DiPasquale, G. and Mellace, D.: Inhibition of arachidonic acid induced mortality in rabbits with several non-steroidal anti-inflammatory agents. Agents and Actions 7/4: 481 (1977).
Doreen, M.S.; Boardman, P.L.; Fowler, P.D. and Poole, P.H.: Diclofenac (Voltarol) in rheumatoid arthritis: A report of a double-blind trial. Rheumatology and Rehabilitation 17: 95 (1978).
Durrigl, T.; Vitaus, M.; Pucar, I. and Miko, M.: Diclofenac sodium (Voltaren): Results of a multi-centre comparative trial in adult-onset rheumatoid arthritis. Journal of International Medical Research 3: 139 (1975).
Fowler, P.D.: Diclofenac sodium (Voltarol): Drug interactions and special studies. Rheumatology and Rehabilitation (Suppl. 2): 60–68 (1979a).
Fowler, P.D.: A double-blind comparison of diclofenac sodium (Voltarol) and placebo in patients with rheumatoid arthritis. Rheumatology and Rehabilitation (Suppl. 2): 75–77 (1979b).
Frank, O.: The treatment of acute gouty arthritis with phenylbutazone and Voltaren; in Wagenhauser (Ed) Voltaren a new non-steroid antirheumatic agent p.62–63 (Huber, Bern, Stuttgart, Vienna 1976).
Fujiwara, A.: Clinical trial of GP-45’840 in orthopedic field. Medical Consultation and New Remedies 9(6): 1147–1152 (1972).
Garcia Rubio, R.: Diclofenac sodico e ibuprofen en arthritis reumatoide. Estudio comparative doble ciego. Prensa Medica Mexicana 41: 270–272 (1976).
Geiger, U.P.; Degen, P.H. and Sioufi, A.: Quantitative assay of diclofenac in biological material by gas-liquid chromatography. Journal of Chromatography 111: 293–298 (1975).
Ghazi, S.A. and Fowler, P.D.: A clinical trial of a new anti-inflammatory/analgesic compound in rheumatoid arthritis —GP 45 840. Journal of International Medical Research 1: 591 (1973).
Gutierrez, G.M.: Antiinflamatorio no esteroide (diclofenac sodico) en traumatologia. Investigacion Medica Internactional 6: 173 (1979).
van Heerden, J.J.: Diclophenac sodium, oxyphenbutazone and placebo in sports injuries of the knee. South African Medical Journal 52: 396 (1977).
Houli, J.; Klein, B. and Coimbra, F.A.: Efficacy and tolerability of Voltaren (diclofenac sodium GP 45,840) in rheumatoid arthritis. Folha Medica 71(6): 685–688 (1975).
Hultin, M. and Olander, K.J.: A clinical trial of the analgesic properties of Voltaren (diclofenac sodium). Scandinavian Journal of Rheumatology (Suppl. 22): 42–45 (1978).
Jobin, F. and Gagnon, F.T.: Inhibition of human platelet aggregation by a dibenzazepine compound (GP 44296) and by N-(2,6-dichlorophenyl)-o-aminophenylacetic acid (GP45840). Canadian Journal of Physiology and Pharmacology 49: 479–481 (1971).
John, V.A.: The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatology and Rehabilitation (Suppl. 2): 22–35 (1979).
De V. Joubert, J.J.: An assessment of the efficacy and tolerability of Voltaren in the treatment of inflammation after extraction of teeth. Journal of the Dental Association of South Africa 32: 581–583 (1977).
Joubert, P.H.; Kushlick, A.R.; McNeill, W.G.; Sheard, E.S.C. and Muller, F.O.: South African multicentre trial with Voltaren in osteo-arthritis of the knee. South African Medical Journal 48: 1973 (1974).
Kajander, A. and Martio, J.: Diclofenac sodium (Voltaren) and naproxen in the treatment of rheumatoid arthritis: A comparative double-blind study. Scandinavian Journal of Rheumatology (Suppl. 22): 57–62 (1978).
Katona, G. and Robles-Gil, J.: Metodo doble ciego, a corto plazo, para evaluar la effcacia del dicofenac sodies en la arthritis reumatoide. Revista Medica del Hospital general (Mex.) 38: 93–100 (1975).
Kendall, M.J.; Thornhill, D.P. and Willis, J.V.: Factors affecting the pharmacokinetics of diclofenac sodium. Rheumatology and Rehabilitation (Suppl. 2): 38–45 (1979).
Kirchheiner, B.; Trang, L. and Wollheim, F.A.: Diclophenac sodium (Voltaren) in rheumatoid arthritis: A double-blind comparison with indomethacin and placebo. International Journal of Clinical Pharmacology 13: 292–297 (1976).
Kittaka, S.; Aizawa, M.; Tokue, I. and Suge, Y.: Efficacy of GP-45’840 on after-pains. Clinical trial with double-blind method. Medical Consultation and New Remedies 9(6): 1123–1134 (1972).
Kozatani, J.; Tada, K. and Shimojo, F.: Absorption and excretion of GP-45,840, an analgesic and anti-inflammatory drug in human. Kiso to Rinsho (Clinical Report) 6(9): 34–40 (1972).
Krupp, P.; Exer, B.; Menassé, R. and Ziel, R.: Neue Aspekte der Entzundungshemmung durch nicht-steroide Antiphlogistika: Wirkung von Voltaren. Schweizerische Medizinische Wochenschrift 105: 646–652 (1975).
Krupp, P.; Menassé, R.; Riesterer, L. and Ziel, R.: The biological significance of inhibition of prostaglandin synthesis; in Lewis (Ed) The Role of Prostaglandins in Inflammation. Proceedings of a Workshop held during the VIIIth European Rheumatology Congress, Helsinki 1975, p. 108–121 (Hans Huber, Bern 1976).
Kruze, D.; Fehr, K. and Boni, A.: Effect of antirheumatic drugs on cathepsin B1 from bovine spleen. Zeitschrift fur Rheumatologie 35(3/4): 94–102 (1976a).
Kruze, D.; Fehr, K.; Menninger, H. and Boni, A.: Effect of antirheumatic drugs on neutral protease from human leucocyte granules. Zeitschrift fur Rheumatologie 35: 337–346 (1976b).
Krzywanek, H.J. and Breddin, K.: Beeinflusst Diclofenac die orale. Antikoagulantientherapie und die Plaettchenaggregation. Medizinische Welt 28: 1843–1845 (1977).
Ku, E.C.; Wasvary, J.M. and Cash, W.D.: Diclofenac sodium (GP 45840, Voltaren), a potent inhibitor of prostaglandin synthetase. Biochemical Pharmacology 24: 641–643 (1975).
Kusuda, M.; Kumamoto, S.; Kurano, A.; Katagiri, H. and Shibata, K.: Clinical trial of an anti-inflammatory agent (GP 45,840) in dysmenorrhea. Japanese Journal of Clinical and Experimental Medicine 49(7): 1919–1925 (1972).
Lehtola, J. and Sipponen, P.: A gastroscopic and histological double-blind study of the effects of diclofenac sodium and naproxen on the human gastric mucosa. Scandinavian Journal of Rheumatology 6: 97–102 (1977).
Limpaphayom, M.; Chotigavanichaya, C.; Kasemsant, D.; Laohasurayotin, S. and Keokarn, T.: A comparative study between diclofenac sodium and indomethacin in degenerative joint and extra-articular disease. Journal of the Medical Association of Thailand 59(8): 349 (1976).
McMahon, M.F. and Cash, H.C.: An open assessment of the efficacy and tolerability of diclofenac sodium in patients with rheumatic disease and a comparative study of diclofenac sodium (Voltarol) with indomethacin in patients with osteoarthritis and rheumatoid arthritis. Rheumatology and Rehabilitation (Suppl. 2) 81–88 (1979).
Maier, R.; Menassé, R.; Riesterer, L.; Pericin, C.; Ruegg, M. and Ziel, R.: The pharmacology of diclofenac sodium (Voltarol). Rheumatology and Rehabilitation (Suppl. 2): 11–21 (1979).
Manz, G. and Franke, M.: Diclofenac sodium in ankylosing spondylitis. Fortschritte der Medizin 95(26): 1706–1708 (1977).
Marcet, A.C.; Barcelo Torrent, P.; Casademont Vilaseca, M.; De Dalmases Gose, R. and Fiol Castano, B.: Double-blind, multicentre, between patient study comparing diclofenac and indomethacin in osteoarthritis treated for 3 months. Clinical and biological evaluation, and statistical analysis of results. Revista Espanola de Reumatismo y Enfermedades Osteoarticulares 20(2): 139–157 (1977).
Marchai, Usobiaga, J.L.: Diclofenac in arthritis. Gaceta Medica de Espanola 50(5): 282 (1976).
Martinez-Elizondo, A.: Acute gout as a model for evaluating drugs with analgesic and anti-inflammatory effects. Translation of a paper presented at the VIIth Pan American Congress on Rheumatology (June 1978).
Martinez-Gallardo, F.: Analgesia postamigdalectomia con diclofenac sodico. Prensa Médica Mexicana 42: 264–266 (1977).
Matru, O.; Penttila, M.; Pesoneu, J.; Salmela, P.; Suhonen, O. and Sonck, T.: Diclofenac sodium (Voltaren) and indomethacin in the ambulatory treatment of rheumatoid arthritis: A double blind multicentre study. Scandinavian Journal of Rheumatology (Suppl. 22): 51–56 (1978).
Mauracher, E. and Dannhorn, R.: Praxisnahe Beurteiling eines neven Antirheumatikums. Therapiewoche 26: 2981–2987 (1976).
Menassé, R.; Hedwall, P.R.; Kraetz, J.; Pesicin, C.; Riesterer, L.; Sallmann, A.; Ziel, R. and Jaques, R.: Pharmacological properties of diclofenac sodium and its metabolites. Scandinavian Journal of Rheumatology (Suppl. 22): 5–16 (1978).
Meyers, O.L.; Quantock, O.P.; Joubert, P.G.; Louw, D.F. Du P.; Marais, D.F.; McDonald Scott, W.A. and Muller, F.O.: A multicentre trial of Voltaren in the treatment of rheumatoid arthritis. South African Medical Journal 48: 2013 (1974).
Michot, F.; Ajdacic, K. and Glaus, L.: A double-blind clinical trial to determine if an interaction exists between diclofenac sodium and the oral anticoagulant acenocoumarol (nicoumalone). Journal of International Medical Research 3: 153 (1975).
Morsdorf, Von K. and Wolf, G.: Zur Wirkungspotenz Neuerer Antiphlogistika. Arzneimittel-Forschung/Drug Research 27: 531 (1977).
Muller, F.O.; Hundt, H.K.L. and Muller, D.G.: Pharmacokinetic and pharmacodynamic implications of long-term administration of non-steroidal anti-inflammatory agents. International Journal of Clinical Pharmacology 15: 397–402 (1977).
Nasution, A.R.: A comparative trial of diclofenac sodium and flufenamic acid in adult patients with extra-articular rheumatism. Indones. Med. Pharm. J. 2: 25–27 (1976).
Oliw, E.; Lunden, I. and Anggard, E.: In vivo inhibition of prostaglandin synthesis in rabbit kidney by non-steroidal antiinflammatory drugs. Acta Pharmacologica et Toxicologica 42: 179–184 (1978).
Ono, K.; Okuda, K. and Kumura, S.: Clinical evaluation of nonsteroidal analgesic and anti-inflammatory agent GP 45,840 for the pain after tooth extraction. Slukai Tenbo 39: 1–21 (1972).
Osnes, M.; Larsen, S.; Eidsaunet, W. and Thom, E.: Effect of diclofenac and naproxen on gastroduodenal mucosa. Clinical Pharmacology and Therapeutics 26: 399 (1979).
Peters, P.; Cooper, C.; Maiorana, K. and Graeme, M.L.: The effect of topically applied agents on ultraviolet erythema in guinea pigs. Agents and Actions 7(5/6): 545 (1977).
Pietschmann, H.; Silberbauer, K.F.; Ring, F. and Sinzinger, H.: Diclofenac and thrombocyte aggregation. Wiener Medizinische Wochenschrift 24(127): 747 (1977).
Rainsford, K.D.: The comparative gastric ulcerogenic activities of non-steroid anti-inflammatory drugs. Agents and Actions 7(5/6): 573 (1977).
Renaud, S. and Lecompte, F.: Thrombosis prevention by coagulation and platelet aggregation inhibitors in hyperlipemic rats. Thrombosis et Diathesis Haemorrhagica 24: 577–586 (1970).
Rheinberger, K.: Wirksamkeit und Vertraeglichkeit von ‘Voltaren’ und Indometacin bei Patienten mit ankylosierender Sponylitis. Therapiewoche 26: 2916–2920 (1976).
Riess, W.; Stierlin, H.; Degen, P.; Faigle, J.W.; Gerardin, A.; Moppert, J.; Sallmann, A.; Sehmid, K.; Schweizer, A.; Sulc, M.; Theobald, W. and Wagner, J.: Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scandinavian Journal of Rheumatology (Suppl. 22): 17–29 (1978).
Rivet, J.-P. and Richard, A.: Voltaren, an anti-inflammatory agent for use in rheumatology. Gazette Médicale de France 84(32): 3547–3554 (1977).
Rosa, G. and Savarese, A.: The use of diclofenac sodium, Voltaren, in orthopaedics. Comparison with indomethacin. Gazzetta Medica Italiana 136(5): 331–337 (1977).
Rosak, von C. and Schoffling, K.: Uber den Einfluss von Diclofenac auf die Glucostaleranz von Diabetikern. Medizinische Welt 28: 1845–1846 (1977).
Rossi, F.A. and Baroni, L.: A double-blind comparison between diclofenac sodium and ibuprofen in osteoarthritis. Journal of International Medical Research 3: 267 (1975).
Sacks, S.: Diclophenac sodium in rheumatoid arthritis and osteoarthritis. South African Medical Journal 48: 213 (1974).
Schlumpf, U.: Der Einfluss von Diclofenac-Natrium auf den Stoffwechsel von Diabetikern unter qualitativer Diat mit und ohne Tolbutamid. Schweizische Medizinische Wochenschrift 108: 28 (1978).
Schubiger, B.I.; Ciccolunghi, S.N. and Tanner, K.: Once daily dose treatment with a non-steroidal antirheumatic drug (Diclofenac) in osteoarthrosis. Journal of International Medical Research 8: 167–173 (1980).
Schultis, K.: Results of short term treatment with ‘Voltaren’ as compared with indomethacin and placebo in non-articular rheumatism; in Wagenhaeuser (Ed) Voltaren, a new non steroid antirheumatic agent p.60–61 (Huber, Berne, Stuttgart Vienna 1976).
Seda, H. and Cardozo, P.C.: Efficacy and tolerability of diclofenac sodium vs ibuprofen in osteoarthritis. Folha Medica 72(6): 633–636 (1976).
Serra, Peralba A.: A clinical trial of a new antirheumatic agent: diclofenac sodium. Medicina Clinica 67: 418–423 (1976).
Shiba, R.; Morishita, M.; Takada, K. and Kawakatsu, K.: Clinical evaluation of a new anti-phlogistic and analgesic agent. Comparative study between sodium-0-(2,6-dichloroanilino) phenylacetate (GP 45840) and indomethacin by double-blind method. Prospect of Dental Field 40(2): 334–342 (1972).
Shiokawa, Y.; Takatori, M. and Sakuma, A.: Multi-centre trial of Voltaren (GP-45’840) on rheumatoid arthritis by double-blind technique. Journal of the Japanese Rheumatology Association 12(3): 271–282 (1972).
Siegmeth, W. and Placheta, W.: A comparison of the short-term effects of ibuprofen and diclofenac in spondylosis. Journal of International Medical Research 6: 369 (1978).
Siraux, P.: Diclofenac (Voltaren) for the treatment of osteo-arthosis: A double-blind comparison with naproxen. Journal of International Medical Research 5: 169 (1977).
Solomon, L. and Abrams, G.: Voltaren in the treatment of rheumatoid arthritis. South African Medical Journal 48: 949 (1974).
Stegink, A.J.: Diclofenac-Na (Voltaren) in the treatment of osteoarthrosis of the spine: A long term (6 months) comparative trial versus indomethacin. Tijdschrift voor Geneesmid-delenonderzoek 5: 41–45 (1977).
Stegink, A.J.: Voltaren (diclofenac-sodium) in arthrosis. Reuma Wereldwijd Ciba-Geigy (NL) 1(3): 12–14 (1977).
Stierlin, H. and Faigle, J.W.: Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II Quantitative determination of the unchanged drug and principal phenolic metabolites in urine and bile. Xenobiotica 9: 611–621 (1979).
Stierlin, H.; Faigle, J.W. and Colombi, A.: Pharmacokinetics of diclofenac sodium (Voltaren) and metabolites in patients with impaired renal function. Scandinavian Journal of Rheumatology (Suppl. 22): 30–35 (1978).
Stierlin, H.; Faigle, J.W.; Sallmann, A.; Kung, W.; Richter, W.J.; Kriemler, H.-P.; Alt, K.O. and Winkler, T.: Biotransformation of diclofenac sodium in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 9: 601–610 (1979).
Szczeklik, A.; Gryglewski, R.J.; Czerniawska-Mysik, G. and Pieton, R.: Asthmatic attacks induced in aspirin-sensitive patients by diclofenac and naproxen. British Medical Journal 2: 231 (1977).
Takashima, T.; Kado, Y. and Ono, T.: Anti-inflammatory effects of GP 45,840. Clinical Reports 6(8) 50–57 (1972).
Tani, I.: Therapeutic results of Voltaren tablets, an analgesic antiinflammatory agent, in pain following tonsillectomy. Medical Consultation and New Remedies 11(8): 274–276 (1974).
Tausch, G.; Eberl, R. and Tuschl, P.: Clinical experience and results of clinical trials with Voltaren in rheumatic diseases. Wiener Medizinische Wochenschrift 126(10): 132–137 (1976).
Taylor, R.J. and Salata, J.J.: Inhibition of prostaglandin synthetase by tolmetin (Tolectin, McN-2559), a new non-steroidal antiinflammatory agent. Biochemical Pharmacology 25: 2479 (1976).
Torralba, T.P.: A short-term between patient comparison of diclofenac sodium and acetylsalicylic acid in osteoarthritis of the knee and hip. Philippine Journal of Internal Medicine 14: 77–82 (1976).
Treadwell, B.L.J, and Tweed, J.M.: Diclofenac in rheumatoid disease. New Zealand Medical Journal 89: 43 (1979).
Tsurumi, K.; Hiramatsu, Y.; Yamaguchi, A.; Hayashi, M.; Shibuya, T. and Fujimura, H.: Effects of GP-45,840 on subchronic experimental inflammations. Folia Pharmacologica Japonica 69: 319–334 (1973).
Tsurumi, K.; Hiramatsu, Y.; Nozaki, M.; Hayashi, M.; Shibuya, T. and Fujimura, H.: Effects of GP 45/840 on acute experimental inflammations. Folia Pharmacologica Japonica 69: 299–318 (1973).
Tsuzuki, M.; Yoshida, S.; Takata, S. and Narita, R.: Clinical trial of GP-45-840 — a new analgesic anti-inflammatory agent. Prospect of Dental Field 41(6): 14 (1973).
Uthgenannt, H.: Gastrointestinale Blutansschiedung unter der Einnahme von Feprazon, Naproxen, Diclofenac. Medizinische Welt 28: 989–992 (1977).
Uthgenannt, H.: Comparative studies on blood loss in the faeces during treatment with Voltaren, naproxen, and acetylsalicylic acid over a period of several weeks; in Wagenhauser (Ed) Voltaren a new, non-steroid antirheumatic agent (diclofenac): Proceedings of a Symposium held during the VIIIth European Rheumatology Congress, Helsinki 1975 (Hans Huber, Bern 1976).
Valtonen, E.J.: A comparative short-term trial with Voltaren (diclofenac sodium) and naproxen in soft tissue rheumatism. Scandinavian Journal of Rheumatology (Suppl. 22): 69–73 (1978).
Vogt, K.-H.: Vergleichende Multicenter-Prüfung von Diclofenac Na und Ketoprofen bei Weichteilrheumatismus. Therapiewoche 26: 2975–2978 (1976).
Wagenhaeuser, F.J. and Narozna, H.: Treatment of osteoarthritis with a new non-steroidal antirheumatic drug. Voltaren. Therapiewoche 26(18): 2947–2957 (1976).
Wagner, J. and Sulc, M.: Binding of diclofenac-Na (Voltaren) to serum proteins of different species and interactions with other drugs in protein binding. Aktuelle Rheumatologie 4: 153 (1979).
Watanabe, S. and Akasaka, Y.: Clinical efficacy of GP-45,840 on lumbago and spondylosis deformans. Medical Consultation and New Remedies 9(5): 933–939 (1972).
Willis, J.V. and Kendall, M.J.: Pharmacokinetic studies on diclofenac sodium in young and old volunteers. Scandinavian Journal of Rheumatology (Suppl. 22): 36–41 (1978).
Willis, J.V.; Kendall, M.J.; Flinn, R.M.; Thornhill, D.P. and Welling, P.G.: The pharmacokinetics of diclofenac sodium following intravenous and oral administration. European Journal of Clinical Pharmacology 16: 405–410 (1979).
Yasunaga, K.: Effects of N-(2,6-dichlorophenyl)-o-amino-phenyl-acetic acid (GP 45,840) upon platelets, blood coagulation, and fibrinolytic activity. Naika Hokan 19(8): 301–306 (1972).
Ziel, R. and Krupp, P.: The significance of inhibition of prostaglandin synthesis in the selection of non-steroidal antiinflammatory agents. International Journal of Clinical Pharmacology 12: 186–191 (1975).
Author information
Authors and Affiliations
Additional information
Manuscript reviewed by: L. Beeley, Department of Therapeutics and Clinical Pharmacology, University of Birmingham, Birmingham, England; F.D. Hart, Harley Street, London, England; D. Kruze, Zurich, Switzerland; S.H. Roth, Phoenix Arthritis Center, Arizona, USA; B. Tait, Clinical School of Medicine, Christchurch Hospital, New Zealand; J.V. Willis, Department of Therapeutics and Clinical Pharmacology, University of Birmingham, Birmingham, England.
‘Voltaren’, ‘Voltarol’ (Ciba-Geigy).
Rights and permissions
About this article
Cite this article
Brogden, R.N., Heel, R.C., Pakes, G.E. et al. Diclofenac Sodium: A Review of its Pharmacological Properties and Therapeutic Use in Rheumatic Diseases and Pain of Varying Origin. Drugs 20, 24–48 (1980). https://doi.org/10.2165/00003495-198020010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198020010-00002